EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effects of low doses of aspirin and dipyridamole on platelet aggregation in the dog coronary artery



Effects of low doses of aspirin and dipyridamole on platelet aggregation in the dog coronary artery



Journal of Pharmacology and Experimental Therapeutics 240(1): 37-43



The circumflex coronary artery of pentobarbital-anesthetized dogs was partially obstructed with an externally applied rigid plastic band. Platelet aggregation at the site of stenosis caused a gradual decline in blood flow in the artery, which was monitored with an electromagnetic flow probe placed proximally to the obstructor. The effects of drugs on platelet aggregation were evaluated by monitoring changes in both the rate and the degree of decline in blood flow. In most dogs, aspirin inhibited intravascular platelet aggregation (ED50 = 1 mg/kg). Dipyridamole, even at doses that severely depressed blood pressure (1 mg/kg), had no effect on platelet aggregation. However, in dogs that had been pretreated with a low dose of dipyridamole (0.2 mg/kg), the antiaggregatory activity of aspirin was enhanced. This potentiation was evident only at low doses of aspirin (0.03 and 0.1 mg/kg), where the drug was 10 times more active; at high aspirin doses, which depressed vascular cyclooxygenase, no potentiation was seen. Further evidence that the mechanism of this synergism may depend on endogenous prostacyclin production at the site of the partial obstruction was seen when cyclooxygenase inhibitors applied topically on the exposed artery eliminated the antiaggregatory effect of low doses of aspirin. It is important to note that the protective effect of dipyridamole and low-dose aspirin was less than that seen at the high doses of aspirin alone, suggesting that the theoretical benefits of platelet-specific doses of aspirin may be overstated.

(PDF 0-2 workdays service: $29.90)

Accession: 005312820

Download citation: RISBibTeXText

PMID: 3543298



Related references

Effect of different aspirin doses on platelet aggregation in patients with stable coronary artery disease. Internal Medicine Journal 33(8): 350-354, 2003

Effects of dipyridamole and aspirin on platelet survival time and exercise hemodynamics in men with coronary artery disease. Clinical Research 27(1): 72A, 1979

Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of Coronary Artery Bypass Graft Occlusion by Aspirin, Dipyridamole and Acenocoumarol/Phenprocoumon Study. Journal of the American College of Cardiology 24(5): 1181-1188, 1994

Effects of dipyridamole and aspirin on shear-induced platelet aggregation in whole blood and platelet-rich plasma. Cerebrovascular Diseases 14(3-4): 234-238, 2002

Effects of aspirin and dipyridamole on platelet aggregation in the wistar rat. Revista de Farmacologia Clinica y Experimental 5(4): 377-382, 1988

Effects of dipyridamole on the glyceryl-trinitrate-induced inhibition of coronary artery muscle tone and platelet aggregation in relation to cyclic nucleotide metabolism. Acta Pharmacologica et Toxicologica 57(2): 88-95, 1985

Platelet survival in coronary artery disease good response to dipyridamole plus aspirin partial response to low dose aspirin alone. Journal of the American College of Cardiology 1(2 PART 2): 707, 1983

Platelet survival in coronary patients good response to dipyridamole plus aspirin partial response to low dose aspirin with or without dipyridamole implications for trials. American Heart Association Monograph (101): III-105, 1983

The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin. Plos One 10(7): E0132629-E0132629, 2016

Effects of aspirin dipyridamole nifedipine and cavinton which act on platelet aggregation induced by different aggregating agents alone and in combination. European Journal of Clinical Pharmacology 42(3): 257-259, 1992

Studies upon coronary venous platelet aggregation in coronary artery disease effect of aspirin. Clinical Research 26(3): 252A, 1978

Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. American Journal of Cardiology 100(4): 610-614, 2007

The effect of single or prolonged administration of aspirin in various doses on platelet aggregation in patients with coronary heart disease. Kardiologiya 24(7): 74-77, 1984

Dipyridamole potentiates the inhibition of platelet aggregation by aspirin (in human platelet rich plasma and whole blood). Journal of Lipid Mediators 4(1): 61-67, 1991